The European Medicines Agency on Friday said it rejected a marketing application for Bristol-Myers Squibb  drug Ixempra, with the regulator worried that damage to nerve cells didn't outweigh the "very small increase" in survival from breast cancer.

Separately, it approved Amgen's Nplate to treat adult chronic immune idiopathic thrombocytopenic purpura, Novartis'  Rasilez HCT for hypertension, Roche's  RoActemra arthritis drug used with methothrexate, Janssen-Cilag International's Stelara for psoriasis, Les Laboratories Servier Valdoxan for major depressive episodes in adults and Jannsen-Cilag's Zevtera for skin and soft tissue infections.